Core Viewpoint - The report outlines the continuous supervision and guidance provided by Guotai Junan Securities for Huahai Qingke Co., Ltd. during the first half of 2025, emphasizing the company's compliance with regulations and its operational performance [2][9]. Summary by Sections Continuous Supervision Work - The sponsor has established a continuous supervision system to ensure the company adheres to regulatory obligations, including information disclosure and operational compliance [2][3]. - The sponsor has assisted the company in developing internal systems and decision-making processes to meet legal and regulatory requirements [3][4]. - The company has maintained transparency in its information disclosure, ensuring it is accurate, complete, and timely [3][4]. Financial Performance - For the first half of 2025, the company reported a revenue of approximately RMB 1.95 billion, a year-on-year increase of 30.28% [17]. - The total profit reached approximately RMB 549.78 million, reflecting an 11.66% increase compared to the previous year [17]. - The net profit attributable to shareholders was approximately RMB 505 million, marking a 16.82% increase [17]. R&D and Innovation - The company has a strong focus on R&D, with R&D expenses accounting for 12.63% of revenue, an increase from 11.72% in the previous year [17][22]. - The company has developed a robust R&D team of 722 members, representing 31.99% of its total workforce [19][20]. - The company has obtained 500 patents and 39 software copyrights, showcasing its commitment to innovation [19][20]. Risk Management - The company faces risks related to core competitiveness, including potential talent loss and technological advancements in the semiconductor equipment industry [9][10]. - The company has established a quality management system to ensure product quality and customer satisfaction [20][21]. - The company is exposed to financial risks, particularly concerning accounts receivable and customer concentration [12][13]. Use of Raised Funds - The company raised a total of RMB 364.43 million through its IPO, with a net amount of RMB 348.99 million after deducting issuance costs [2][23]. - As of June 30, 2025, the company has utilized RMB 111.58 million of the raised funds for designated projects [23]. - The company has ensured compliance with regulations regarding the management and use of raised funds [23].

Summary of Key Points Core Viewpoint - The company is utilizing its own funds to pay for investment projects and will replace these funds with raised capital, ensuring operational efficiency and compliance with regulatory requirements [1][5]. Fundraising Overview - The company raised a total of RMB 820,665.87 million by issuing 80,229,335 shares at RMB 102.29 per share, with a net amount of RMB 812,459.21 million after deducting fees [1][2]. - The total commitment for investment projects was RMB 1,000,000.00 million, with an adjusted total of RMB 811,816.24 million [2]. Investment Project Details - The main projects funded include the Micro Semiconductor Industrialization Base Construction Project (RMB 317,000.00 million) and Technology Reserve Fund (RMB 119,816.24 million) [2]. Reasons for Using Own Funds - The company used its own funds for certain project expenses due to regulatory requirements regarding employee compensation and social insurance payments, which cannot be processed through the raised capital account [2][3]. Operational Process - The company will compile a detailed list of expenses paid with its own funds, followed by a transfer of equivalent amounts from the raised capital account to its own accounts [3]. Impact on the Company - This approach is expected to enhance operational management efficiency and ensure the smooth progress of investment projects without negatively affecting normal operations [3][4]. Compliance and Approval - The decision to use own funds and replace them with raised capital has been approved by the company's board and supervisory committee, adhering to relevant regulations and internal management systems [4][5].

王 胜 ??????????????雾??仍??? 杨 ?????????????? ??????O????????????????? ?????????????π????????ā????????、????? ????????????π????、?ā??????ā?徐???????????????? 、??к??2023 ???????????????????????????? к?????ъ?????? ?к?????、???к???? ?к????? ?、 ??к????????? 1 ?üü????????????????? ????????、??? 2025 ?????????有?仍??亩???y由 ???????o???π? a????????????? ?a??????????????? ????? 2025 ? 4 ? 24 ??????????????????????? ???a????????????享????? 2025 ??????????????????? ??壳? 2025 ???????????仍ㅠ?? 11,250.00 s?????????????????????? ???? ...

Group 1 - The articles discuss ongoing developments in the agricultural sector, particularly focusing on land usage and productivity metrics [1][2] - There is a mention of specific acreage figures, indicating that certain areas remain underutilized despite potential for growth [1][2] - The timeline for projected changes in land use and productivity extends to 2025, highlighting future expectations for the industry [1][2] Group 2 - The articles emphasize the importance of regulatory reviews and approvals in the agricultural sector, which may impact land development and usage [1][2] - There are references to ongoing assessments of land productivity, suggesting that current practices may not be fully optimized [1][2] - The discussion includes potential shifts in land management strategies as the industry looks towards future sustainability and efficiency [1][2]

国泰海通证券股份有限公司 关于上海益诺思生物技术股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海益诺思生物技术股份有限公司（以下简称"益诺思"、"公司"或"发行人"） 首次公开发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保 荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交易所科创板上市公 司自律监管规则适用指引第 1 号——规范运作》等有关法律法规和规范性文件的 要求，就益诺思使用部分暂时闲置募集资金进行现金管理的事项进行了审慎核查， 并发表如下核查意见: 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海益诺思生物技术股份有 限公司首次公开发行股票注册的批复》 （证监许可〔2024〕762 号），公司首次公 开发行人民币普通股（A 股）3,524.4904 万股（以下简称"本次发行"），每股发 行价格为人民币 19.06 元，本次发行募集资金总额 67,176.79 万元，扣除发行费 用后，募集资金净额为 60,964.49 万元。上述募集资金已到位，经立信会计师事 务所（特殊普 ...

Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the normal operation of fundraising investment projects and guarantees the safety of funds [1][4][8]. Fundraising Basic Information - The company raised a total of RMB 3,255,615,848.10 from its initial public offering of 32,984,963 shares at a price of RMB 9.87 per share, with all funds received and verified by an accounting firm [1][2]. Cash Management Purpose - The cash management aims to improve the efficiency of fund usage, increase cash asset returns, and protect shareholder interests while ensuring that fundraising investment projects are not impacted [4][5]. Cash Management Products - The company plans to invest in high-safety, liquid, principal-protected products, including but not limited to time deposits, large certificates of deposit, and notice deposits [4][5]. Investment Limit and Duration - The company intends to use up to RMB 130,000 million of temporarily idle funds for cash management, with a validity period of 12 months from the board's approval [4][5]. Implementation Method - The board authorizes the management to make investment decisions and sign relevant legal documents, with the finance management center responsible for organizing the implementation [4][5]. Information Disclosure - The company will fulfill its information disclosure obligations in accordance with relevant regulations and guidelines [5][8]. Cash Management Income Distribution - The income from cash management will be used to supplement any shortfall in the investment amounts of fundraising projects, and the funds will be returned to the fundraising special account upon maturity [5][8]. Impact on Company Operations - The cash management will not affect the normal operation of fundraising investment projects or the company's main business, and it is expected to enhance overall performance and shareholder returns [5][8]. Review Procedures - The board and supervisory board have approved the cash management proposal, confirming that it aligns with regulatory requirements and does not harm the interests of the company or its shareholders [7][8]. Sponsor's Verification Opinion - The sponsor has verified that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of the raised funds [8].

Core Viewpoint - The company is utilizing excess raised funds to replace previously invested self-raised funds for ongoing projects, ensuring compliance with regulatory requirements and maintaining the integrity of fundraising purposes [1][5][7]. Fundraising Overview - The company was approved to issue 40 million shares at a price of RMB 28.82 per share, raising a total of RMB 1,152.8 million, with a net amount of RMB 1,049.66 million after deducting issuance costs. The excess funds raised amounted to RMB 341.66 million [1][2]. Investment Project Details - The total investment for the planned projects is RMB 1,009.62 million, with adjusted investment amounts for specific projects, including the rehabilitation equipment research and exhibition center, which saw its total investment increase from RMB 146.73 million to RMB 228.73 million [2][3]. Use of Excess Funds - The company decided to use RMB 79.12 million of the excess funds for the construction of the rehabilitation medical device industrial park, specifically for the research center and related facilities. This decision was approved in the board meeting held on April 23, 2025 [3][4]. Replacement of Self-raised Funds - The company plans to replace RMB 12.91 million of self-raised funds that were previously invested in the rehabilitation medical device industrial park with the excess funds. This replacement was approved in the board meeting on August 27, 2025 [4][5]. Compliance and Verification - The supervisory board and the accounting firm confirmed that the use of excess funds complies with relevant regulations and does not affect the normal implementation of investment projects. The replacement of funds was verified by the accounting firm, ensuring adherence to regulatory standards [5][7][8].

Core Viewpoint - The acquisition of Keda Quantum Technology Co., Ltd. by China Telecom Quantum Information Technology Group Co., Ltd. is progressing according to regulatory requirements, with the financial advisor providing ongoing supervision and confirming compliance with disclosure obligations [2][4][7]. Group 1: Acquisition Details - The acquisition allows the acquirer to hold more than 30% of the shares in the listed company, which typically requires a public offer unless exempted under specific conditions [4][5]. - The acquirer has committed to not transferring the newly issued shares for three years, and the shareholders' meeting has approved the exemption from making a public offer [4][5]. - The acquisition has received necessary approvals from the State-owned Assets Supervision and Administration Commission and the Shanghai Stock Exchange, with the registration from the China Securities Regulatory Commission also granted [7]. Group 2: Compliance and Operations - During the ongoing supervision period, the acquirer and its concerted actions have adhered to legal and regulatory requirements in exercising shareholder rights [7][8]. - The acquirer has made commitments regarding the authenticity of information, maintaining the independence of the listed company, and avoiding conflicts of interest [8]. - No significant changes to the main business operations or asset restructuring plans of the listed company are anticipated within the next 12 months [9][10]. Group 3: Management Changes - Following the acquisition, there will be changes in the board of directors, with the acquirer entitled to nominate a significant number of directors and supervisors [10][11]. - The resignation of several current directors and supervisors has been submitted, with new appointments planned to align with the acquisition agreement [12][13]. - The company will modify its articles of association to reflect changes in registered capital and share structure post-acquisition [15][16].

国泰海通证券股份有限公司 关于杭州博拓生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为杭 州博拓生物科技股份有限公司（以下简称"博拓生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等法律法规和规范性文件的要求，对博拓生物使用部分暂时闲置募集资 金进行现金管理事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于2021年7月27日 出具的《关于同意杭州博拓生物科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2021〕2497号），公司获准向社会公开发行人民币普通股2,666.6667 万股，每股发行价格为人民币34.55元，募集资金总额为92,133.33万元，扣除发行 费用9,196.41万元（不含增值税）后，募集资金净额为82,936.92万元。上述募集资 金到位情况已经中汇会计师事务所（特殊普通合伙）审验 ...

Core Viewpoint - The company has decided to permanently supplement its working capital with surplus funds from completed fundraising projects, following a thorough review and approval process [1][8][9] Fundraising Overview - The company raised a net amount of 829.37 million yuan after deducting issuance costs of 91.96 million yuan [1] - The funds were verified by an accounting firm and stored in a dedicated account with a tripartite supervision agreement [1] Investment Project Status - As of June 30, 2025, the company has invested a total of 733.62 million yuan in various projects, with a remaining balance of 299.67 million yuan [2] - The "Annual Production of 400 Million Medical Devices (In Vitro Diagnostics) Expansion and Upgrade Project" has been completed and is now operational [3][4] Surplus Funds and Their Use - The company has approved the use of 160.57 million yuan in surplus funds to support daily operations, following the completion of certain projects [3][6] - The surplus funds were generated due to cost-saving measures during project implementation, including optimized production processes and reduced personnel costs [4][6] Financial Performance of Completed Projects - The completed project generated revenues of 47.11 million yuan in 2023, 112.07 million yuan in 2024, and 13.92 million yuan in the first half of 2025, which did not meet the expected performance [6] Decision-Making Process - The decision to use surplus funds for working capital was made after careful consideration of market conditions and project completion [7][8] - The board of directors approved the proposal without requiring a shareholder meeting [7] Conclusion from the Sponsor Institution - The sponsor institution has confirmed that the decision to use surplus funds aligns with regulatory requirements and is beneficial for the company's long-term development [8][9]